Dr. Martin Kampmann heads the CRISPRi/a technology (CRISPR core). Dr. Kampmann is an assistant professor at the University of California, San Francisco. Dr. Kampmann’s lab is at the forefront of developing technologies to perturb gene function in a wide range of biological systems. Dr. Kampmann co-developed a genetic screening platform that exploits catalytically dead Cas9 (dCas9) to recruit transcriptional repressors or activators to endogenous genes to enable inducible and reversible repression (CRISPRi) and activation (CRISPRa) of genes in human cells, enabling genome-wide loss- and gain-of-function screens. This screening platform is based on a quantitative framework for massively parallel screens they had previously developed for RNA interference-based screens. Importantly, CRISPRi overcomes the problem of off-target effects that has plagued RNAi-based approaches, resulting in high specificity while maintaining high sensitivity.